Ampio Pharmaceuticals (AMPE) announces preliminary results of the pain score portion of the...

|About: Ampio Pharmaceuticals, ... (AMPE)|By:, SA News Editor

Ampio Pharmaceuticals (AMPE) announces preliminary results of the pain score portion of the expansion phase of Ampion in-Knee (AIK) trial, which was recently completed in Australia. Preliminary analysis suggests Ampion may be a therapeutic alternative to steroids for osteoarthritis, with a very favorable safety profile. Shares are flat at $4.08. (submitted by M. E. Garza)